GSA Capital Partners LLP Purchases New Shares in Compass Pathways PLC Sponsored ADR $CMPS

GSA Capital Partners LLP purchased a new position in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) in the third quarter, HoldingsChannel.com reports. The firm purchased 67,879 shares of the company’s stock, valued at approximately $389,000.

A number of other institutional investors also recently bought and sold shares of the business. Nantahala Capital Management LLC raised its holdings in shares of Compass Pathways by 47.7% in the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock valued at $11,704,000 after buying an additional 1,350,698 shares during the last quarter. Hsbc Holdings PLC acquired a new position in Compass Pathways in the 2nd quarter valued at about $3,011,000. 22NW LP increased its position in Compass Pathways by 36.5% in the 2nd quarter. 22NW LP now owns 882,844 shares of the company’s stock valued at $2,472,000 after acquiring an additional 236,285 shares during the period. Balyasny Asset Management L.P. raised its stake in Compass Pathways by 38.0% during the 2nd quarter. Balyasny Asset Management L.P. now owns 854,840 shares of the company’s stock valued at $2,394,000 after acquiring an additional 235,345 shares during the last quarter. Finally, Schroder Investment Management Group acquired a new stake in Compass Pathways during the 2nd quarter worth approximately $1,525,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on CMPS shares. Canaccord Genuity Group boosted their target price on Compass Pathways from $15.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Royal Bank Of Canada boosted their price objective on shares of Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a research note on Wednesday, February 18th. Compass Point set a $15.00 target price on shares of Compass Pathways in a research note on Thursday, February 12th. Morgan Stanley lifted their target price on shares of Compass Pathways from $11.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Finally, Lifesci Capital raised shares of Compass Pathways to a “strong-buy” rating in a report on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $17.56.

Compass Pathways Stock Performance

Shares of CMPS opened at $7.44 on Thursday. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.55. Compass Pathways PLC Sponsored ADR has a 52-week low of $2.25 and a 52-week high of $8.90. The company has a 50-day simple moving average of $6.94 and a 200-day simple moving average of $6.03. The company has a market capitalization of $714.39 million, a PE ratio of -2.74 and a beta of 1.92.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.